Clinical Trial Detail

NCT ID NCT03126916
Title Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Children's Oncology Group
Indications

neuroblastoma

nodular ganglioneuroblastoma

Therapies

Doxorubicin

131I-MIBG

Sargramostim

Etoposide

Melphalan

Busulfan

Isotretinoin

Vincristine

Cisplatin

Cyclophosphamide

Thiotepa

Crizotinib

dexrazoxane

Carboplatin

Aldesleukin

Topotecan

Dinutuximab

Age Groups: adult child

Additional content available in CKB BOOST